Opinion Former Article

Diabetes UK response to degludec research published in The Lancet

Dr Iain Frame, Director of Research at leading health charity Diabetes UK, said: "This is an incremental step forward in the treatment of Type 2 diabetes only.

The research shows that degludec has the same effectiveness on blood glucose management as an insulin already on the market. However, the study does suggest some additional benefits. For people with Type 2 diabetes who use insulin and find daily insulin injections unpleasant, degludec could reduce the number of injections to three times a week. However, there are trials currently taking place testing weekly and oral therapies which have the potential of offering much more freedom.

"The study also suggests that degludec could reduce the frequency of hypos, a serious short term complication that can be debilitating and impact on a person's quality of life. "This work is still in its infancy and more trials are still needed to prove its effectiveness and safety as a routine treatment for people with Type 2 diabetes."

Maria Lam
Media Manager

Diabetes UK
Macleod House, 10 Parkway, London NW1 7AA

Tel: 020 7424 1166
Press: 020 7424 1165


A study assessing a new longer-acting form of insulin-degludec- has shown that when given once daily it is as effective at controlling blood sugar as existing insulin glargine injections but with lower rates of hypoglycaemia. Consistent with its long acting properties the study also demonstrated that patients could achieve the same level of glucose control when the insulin was administered just three times a week instead of daily. The Article, published Online First and in this week's Lancet, is written by Professor Bernard Zinman, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, ON, Canada, and colleagues.

Insulin degludec is a unique type of injectable insulin currently in development. In this 16-week, randomized phase 2 proof of concept trial , participants aged 18-75 years with type 2 diabetes and glycosylated haemoglobin (HbA1C) of 7.0-11.0% were enrolled and treated at 28 clinical sites in Canada, India, South Africa, and the USA. A value of 7.0% or under is usually the target for diabetes patients. Patients were randomly allocated to receive insulin degludec once daily, insulin degludec three times weekly or insulin glargine once daily. At study end, mean HbA1C levels were much the same across treatment groups ranging from 7.2% to 7.5%. Fewer participants suffered hypoglycaemia (abnormally low blood sugar) in the insulin degludec once daily compared to the other groups and the number of adverse events was much the same across groups, with no apparent treatment-specific pattern.

Professor Zinman* says: "Because of its ultra-long action profile, insulin degludec injected three times weekly appears to provide similar glucose control to insulin glargine once daily. This new basal insulin analogue might be a valuable addition to clinical practice.However the safety, efficacy, and optimum use of treatment regimens for insulin degludec will need to be established in larger phase 3 trials."

In a linked Comment, Dr Yogish C Kudva and Dr Ananda Basu, Mayo Clinic College of Medicine, Rochester, MN, USA, say: "Doses given three times a week might improve adherence, improve glycaemic control without an increase in hypoglycaemia, and cause less disruption to the patient's lifestyle." They add that lifestyle changes (diet and exercise) are inexpensive and favourable to patients, yet need constant re-emphasis, even as the numbers of long-acting drugs for type 2 diabetes increase.

Huw Beale
Senior Media Officer

Diabetes UK
Macleod House
10 Parkway, London NW1 7AA

020 7424 1152 : direct line
020 7424 1165 : press line
020 7424 1092 : ISDN
07711 176 028 : out of hours mobile
020 7424 1080 : fax
huw.beale@diabetes.org.uk : email
www.diabetes.org.uk | www.facebook.com | www.twitter.com : web

More Articles by Diabetes UK ...

Disclaimer: Press releases published on this page are from key opinion formers who promote their organisation's activities by subscribing to a campaign site within politics.co.uk. politics.co.uk does not endorse, edit, or attempt to balance the opinions expressed on this page. The content of press releases are wholly the responsibility of the originating company or organisation.


Load in comments